JP2021514193A - Ｂｃｍａ結合抗体及びその使用 - Google Patents

Ｂｃｍａ結合抗体及びその使用 Download PDF

Info

Publication number
JP2021514193A
JP2021514193A JP2020544223A JP2020544223A JP2021514193A JP 2021514193 A JP2021514193 A JP 2021514193A JP 2020544223 A JP2020544223 A JP 2020544223A JP 2020544223 A JP2020544223 A JP 2020544223A JP 2021514193 A JP2021514193 A JP 2021514193A
Authority
JP
Japan
Prior art keywords
seq
bcma
antibody
cell
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020544223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514193A5 (enExample
Inventor
アブバシアン マハン
アブバシアン マハン
チャン ヘンリー
チャン ヘンリー
ハリハラン カンダサミー
ハリハラン カンダサミー
サン ジョンフン
サン ジョンフン
ウルムセル アンドリュー
ウルムセル アンドリュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2021514193A publication Critical patent/JP2021514193A/ja
Publication of JP2021514193A5 publication Critical patent/JP2021514193A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020544223A 2018-02-21 2019-02-20 Ｂｃｍａ結合抗体及びその使用 Pending JP2021514193A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633152P 2018-02-21 2018-02-21
US62/633,152 2018-02-21
PCT/US2019/018698 WO2019164891A1 (en) 2018-02-21 2019-02-20 Bcma-binding antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2021514193A true JP2021514193A (ja) 2021-06-10
JP2021514193A5 JP2021514193A5 (enExample) 2023-08-29

Family

ID=65686040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544223A Pending JP2021514193A (ja) 2018-02-21 2019-02-20 Ｂｃｍａ結合抗体及びその使用

Country Status (15)

Country Link
US (2) US11401336B2 (enExample)
EP (1) EP3755718A1 (enExample)
JP (1) JP2021514193A (enExample)
KR (1) KR20200123155A (enExample)
CN (1) CN112272675A (enExample)
AR (1) AR115257A1 (enExample)
AU (1) AU2019223076A1 (enExample)
BR (1) BR112020017053A2 (enExample)
CA (1) CA3092037A1 (enExample)
EA (1) EA202091974A1 (enExample)
IL (1) IL276548A (enExample)
MX (1) MX2020008718A (enExample)
SG (1) SG11202007495SA (enExample)
TW (1) TW202000701A (enExample)
WO (1) WO2019164891A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024541935A (ja) * 2021-10-27 2024-11-13 ヤンセン バイオテツク，インコーポレーテツド ヒト及びサル組織における増強されたｂｃｍａ免疫組織化学検出のための方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005983A (es) 2019-11-18 2022-09-07 Janssen Biotech Inc Receptores del antígeno quimérico anti-cd79, células car-t, y usos de estos.
AU2021263408A1 (en) * 2020-04-30 2022-10-27 Bristol-Myers Squibb Company Methods of treating cytokine-related adverse events
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
US12692314B2 (en) * 2022-05-06 2026-07-28 IGI Therapeutics SA CD3/BCMA/CD38 trispecific antibodies
PY2342675A (es) * 2022-06-09 2023-12-11 Biocad Joint Stock Co Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente a bcma, y uso del mismo
WO2025184567A1 (en) * 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies
WO2026072709A1 (en) 2024-09-25 2026-04-02 Orna Therapeutics, Inc. Chimeric antigen receptors targeting bcma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223111A1 (en) * 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5998656A (en) 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5475011A (en) 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5763477A (en) 1994-07-22 1998-06-09 Dr. Reddy's Research Foundation Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III
AU5305796A (en) 1995-03-10 1996-10-02 Hauser Chemical Research, Inc. Cephalomannine epoxide, its analogues and a method for preparing the same
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
DE69740140D1 (de) 1996-07-24 2011-04-14 Celgene Corp Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
FI990180A7 (fi) 1996-08-12 1999-03-08 Celgene Corp Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
TR200101500T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı.
WO2000055134A1 (en) 1999-03-18 2000-09-21 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
HK1049997B (en) 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
AU2005311888A1 (en) 2004-12-01 2006-06-08 Celgene Corporation Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
BRPI0607239A2 (pt) 2005-01-25 2009-08-25 Celgene Corp usos de uma quantidade terapeuticamente ou profilaticamente eficaz de 4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol-1,3-d iona, de (3r)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, e de (3s)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, ou um sal ou solvato farmaceuticamente aceitável das mesmas, composição farmacêutica, e, forma de dosagem unitária simples
CA2822094C (en) 2005-08-31 2015-10-27 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
HUE035389T2 (en) 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
WO2010032061A1 (en) * 2008-09-19 2010-03-25 Medimmune Llc Antibodies against sonic hedgehog homolog and uses thereof
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
RU2611007C2 (ru) 2011-03-11 2017-02-17 Селджин Корпорейшн Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
BR112016024546A2 (pt) * 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
AU2015292744C1 (en) * 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table
TWI700298B (zh) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向ｂ細胞成熟抗原之嵌合型抗原受體類
HUE057285T2 (hu) * 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
JP6901493B2 (ja) * 2015-11-13 2021-07-14 アメリカ合衆国 抗ｂｃｍａポリペプチド及びタンパク質
NZ746700A (en) * 2016-04-01 2023-04-28 Kite Pharma Inc Bcma binding molecules and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223111A1 (en) * 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024541935A (ja) * 2021-10-27 2024-11-13 ヤンセン バイオテツク，インコーポレーテツド ヒト及びサル組織における増強されたｂｃｍａ免疫組織化学検出のための方法

Also Published As

Publication number Publication date
AU2019223076A1 (en) 2020-10-08
WO2019164891A1 (en) 2019-08-29
EA202091974A1 (ru) 2020-12-08
TW202000701A (zh) 2020-01-01
IL276548A (en) 2020-09-30
MX2020008718A (es) 2020-12-07
US20220324991A1 (en) 2022-10-13
KR20200123155A (ko) 2020-10-28
WO2019164891A9 (en) 2020-09-17
CN112272675A (zh) 2021-01-26
AR115257A1 (es) 2020-12-16
EP3755718A1 (en) 2020-12-30
BR112020017053A2 (pt) 2020-12-15
CA3092037A1 (en) 2019-08-29
US11401336B2 (en) 2022-08-02
SG11202007495SA (en) 2020-09-29
US20200399386A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
US20220324991A1 (en) Bcma-binding antibodies and uses thereof
JP7605912B2 (ja) Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞
US20210038646A1 (en) Chimeric antigen receptors targeting the tumor microenvironment
US20200024358A1 (en) Trispecific antigen binding proteins
TW201936633A (zh) 標靶至cd70的嵌合抗原受體
IL268895B2 (en) Compositions and methods for inhibition of lineage specific proteins
KR20170128234A (ko) Ror1에 특이적인 항체 및 키메라 항원 수용체
CN114149511A (zh) 靶向b细胞成熟抗原的嵌合抗原受体
KR20170057298A (ko) Cd19에 특이적인 항체 및 키메라 항원 수용체
EP4442701A1 (en) Combination of molecular switch regulation type chimeric antigen receptor cell and antibody, and use thereof
WO2023006118A1 (en) Anti-cd33 antibodies and uses thereof
KR20230015348A (ko) Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물
JP2023519970A (ja) 抗原ターゲティングされた免疫療法における抗原陰性細胞死の増進
JP2025529878A (ja) 新規な抗ｌｉｌｒｂ２抗体及びその使用
WO2023006117A1 (en) Antibodies against cll1 and constructs thereof
US20250333526A1 (en) Antibodies capable of binding to ox40, variants thereof and uses thereof
EP4378953A1 (en) Cd229 targeting moiety for the tratment of cd229 positive cancer
WO2024140641A1 (zh) 靶向ror1的抗原结合蛋白
EA044652B1 (ru) Связывающие bcma антитела и их применение
US20240226298A1 (en) Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
HK40108858A (en) Antibodies against cll1 and constructs thereof
JP2024532167A (ja) 抗ｆｌｔ３抗体、ｃａｒ、ｃａｒ ｔ細胞、及び使用方法
WO2026001894A1 (zh) 靶向axl的嵌合抗原受体及其用途
HK40108020A (zh) 抗cd33抗体及其用途
TW202540189A (zh) 在組合療法中能夠結合ｏｘ４０之抗體

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230515

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240402